Vantia Therapeutics appoints new chief executive
Andrew Crockett wins promotion after 12 months with pharma company
Since joining the Southampton, UK-based emerging pharmaceutical firm in 2009 as vice president of business development, Crockett has made a significant contribution to Vantia’s corporate development. He was previously with US specialist pharma company ZARS Pharma.
Martin Murphy, non-executive chairman of Vantia, said: ‘We are very pleased that Andrew Crockett has accepted the position as ceo. Vantia has made considerable progress over the past two years in advancing its pipeline of novel small molecule drug candidates into Phase II clinical trials. We wish Jim Phillips, the former ceo, well and appreciate his contribution to the team. The management team has created a solid platform for Vantia and we are therefore very pleased that Andrew will continue the great work that has been started.’
Crockett added: ‘We are looking forward to an exciting second half of the year when we expect important clinical data from our Phase IIa efficacy study in dysmenorrhoea and from our Phase IIb study in nocturia.’
Vantia Therapeutics develops novel, small molecule drugs targeting large, underserved medical markets. Formed in 2008 as a spin-out of Ferring Research’s small molecule r&d, it has two clinical phase products, VA106483 for the treatment of nocturia and VA111913 for the treatment of dysmenorrhoea, as well as preclinical and discovery programmes based on protease inhibition with potential in the areas of oncology and inflammation.
You may also like
Research & Development
COVID-19 immunity lowers the risk of a new pandemic
Researchers at the MRC-University of Glasgow Centre for Virus Research have demonstrated that the likelihood of the emergence of a new SARS-type virus pandemic has been significantly reduced by population-wide immunity to SARS-CoV-2
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Cytiva enters research partnership with SRTIGET for next-gen genomic medicine
The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
Research & Development
Just – Evotec Biologics wins BARDA contract to optimise antibody biomanufacturing against Ebola and Sudan virus
Just – Evotec Biologics has been selected by BARDA to develop scalable, high-yield manufacturing processes for a monoclonal antibody cocktail targeting filovirus diseases under a multi-year programme valued at up to $10m
Research & Development
ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology
Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents